Aquestive Therapeutics, Inc. · NASDAQ (us_market)
Healthcare · Drug Manufacturers - Specialty & Generic · United States
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; EMYLIF, an oral film formulation of riluzole; ONDIF, an oral soluble film formulation of ondansetron; SYMPAZAN, an oral soluble film formulation of clobazam used for the treatment of seizures associated with a rare, intractable form of epilepsy; KYNMOBI, a sublingual film formulation of apomorphine; and AZSTARYS, an fda-approved, once-daily product for the treatment of ADHD in patients age 6 years or older. The company's proprietary pipeline products include Anaphylm, an epinephrine sublingual film, which is in phase 3 clinical trial for the emergency treatment of allergic reactions, including anaphylaxis; and AQST-108, a topical gel that is in phase 2 clinical trial for the treatment of alopecia areata. In addition, it develops PharmFilm technology for patients suffering from certain central nervous system disorders; and Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2025-12-08$6.62 RISE2026-03-24$3.88 PEAK2026-05-14$4.73 157d | -41.4% 106d | Missed | Missed | — | — | +21.9% 51d | Missed |
DROP2025-10-20$7.49 RISE2026-01-30$2.95 PEAK2026-03-04$4.37 135d | -60.6% 102d | Missed | Missed | — | — | +48.1% 33d | Missed |
DROP2025-10-20$7.49 RISE2025-11-13$5.30 PEAK2025-12-08$6.62 49d | -29.2% 24d | Missed | Missed | — | — | +24.9% 25d | Missed |
DROP2025-01-02$3.67 RISE2025-05-14$2.22 PEAK2025-07-17$4.37 196d | -39.5% 132d | Missed | Missed | — | — | +96.8% 64d | Missed |
DROP2024-11-27$5.16 RISE2025-04-08$2.37 PEAK2025-07-03$3.72 218d | -54.1% 132d | Missed | Missed | — | — | +57.0% 86d | Missed |
DROP2024-10-29$5.66 RISE2025-03-10$2.54 PEAK2025-06-04$3.41 218d | -55.1% 132d | Missed | Missed | — | — | +34.3% 86d | Missed |
DROP2024-03-15$6.09 RISE2024-06-25$2.31 PEAK2024-09-19$5.20 188d | -62.1% 102d | Missed | Missed | — | — | +125.1% 86d | Missed |
DROP2023-12-04$2.47 RISE2023-12-20$1.87 PEAK2024-03-15$6.09 102d | -24.3% 16d | Missed | Missed | — | — | +225.7% 86d | Missed |
DROP2023-06-01$2.31 RISE2023-10-05$1.30 PEAK2023-12-04$2.47 186d | -43.9% 126d | Missed | Missed | — | — | +90.7% 60d | Missed |
DROP2023-05-11$2.49 RISE2023-07-24$1.55 PEAK2023-08-01$2.24 82d | -37.8% 74d | Missed | Missed | — | — | +44.5% 8d | Missed |
DROP2022-11-15$1.05 RISE2023-03-15$0.73 PEAK2023-05-11$2.49 177d | -31.0% 120d | Missed | Missed | — | — | +243.4% 57d | Missed |
DROP2022-08-24$1.56 RISE2022-12-28$0.77 PEAK2023-01-17$1.00 146d | -50.4% 126d | Missed | Missed | — | — | +29.4% 20d | Missed |
DROP2022-08-12$1.73 RISE2022-11-02$0.84 PEAK2022-11-11$1.05 91d | -51.4% 82d | Missed | Missed | — | — | +25.0% 9d | Missed |
DROP2022-03-03$3.04 RISE2022-07-01$0.63 PEAK2022-08-12$1.73 162d | -79.3% 120d | Missed | Missed | — | — | +174.6% 42d | Missed |
DROP2021-11-26$6.37 RISE2022-02-23$2.28 PEAK2022-03-03$3.04 97d | -64.2% 89d | Missed | Missed | — | — | +33.3% 8d | Missed |
1–15 / 23 1 / 2 | |||||||
Discover Xeris Biopharma (XERS) revenue growth and an inflection point driven by its expanding injectable portfolio.
As you might know, Aquestive Therapeutics, Inc. ( NASDAQ:AQST ) just kicked off its latest quarterly results with some...
Aquestive Therapeutics Inc (AQST) reports a 66% revenue increase and outlines strategic milestones, despite challenges in product launch timelines.
Aquestive Therapeutics (NASDAQ:AQST) said it remains on track to resubmit its new drug application for Anaphylm, its epinephrine sublingual film for severe allergic reactions, in the third quarter of 2026, while reporting higher first-quarter revenue and a narrower net loss. On the company’s first-
Aquestive Therapeutics, Inc. (AQST) Q1 2026 Earnings Call May 14, 2026 8:00 AM EDTCompany ParticipantsDaniel Barber - CEO, President & DirectorErnie...
2026-05-14. The following slide deck was published by Aquestive Therapeutics, Inc.
Presentation Operator MessageOperator Good day, and thank you for standing by. Welcome to the First Quarter 2026 Aquestive Therapeutics Earnings Conference Call. [Operator Instructions] Please be...
U.S. stocks rose, with Dow Jones up 300 points. STAA shares surged after better-than-expected results. Other big gainers include POET, STUB, MSC, ARX, CSCO, PCT, WOLF, CPA, ONDS, KLAR, and RDW.
While the top- and bottom-line numbers for Aquestive Therapeutics (AQST) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of +50.00% and +33.22%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Gainers Staar Surgical (NASDAQ:STAA) shares rose 15.3% to $33.9 during Wednesday's after-market session. The company's market cap stands at $1.3 billion. As per the press release, Q1 earnings came out today. Precision Optics Corp (NASDAQ:POCI) shares moved upwards by 15.21% to $5.3. The market value of their outstanding shares is at $49.6 million. As per the news, the Q3 earnings report came out today. Aquestive Therapeutics (NASDAQ:AQST) stock moved upwards by 13.55% to $4.69. The market value
After the closing bell on Wednesday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.
WARREN, N.J. — WARREN, N.J. — Aquestive Therapeutics Inc. on Wednesday reported a loss of $8.1 million in its first quarter. On a per-share basis, the Warren, New Jersey-based company said it...
Aquestive Therapeutics (NASDAQ:AQST) affirms FY2026 sales outlook from $46.000 million-$50.000 million to $46.000 million-$50.000 million vs $48.072 million estimate.
Aquestive Therapeutics (NASDAQ:AQST) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.15) by 53.33 percent. This is a 70.83 percent increase over losses of $(0.24) per share
Reaffirms guidance to resubmit Anaphylm™ sublingual film NDA in Q3 2026Affirms existing clinical data is sufficient for submitting regulatory applications in Canada, European Union, and the United...
WARREN, N.J., May 12, 2026 -- Aquestive Therapeutics, Inc. , a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery...
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| AQST | -4.29% | -4.51% | -37.77% | +48.34% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | -7.25% | +1.20% | -34.33% | +35.65% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| StateStreet | passive | 2.55M | $10.57M | 0.00% | Added+3.4% | 2026-03-31 |
| TwoSigma | quant | 1.14M | $4.73M | 0.00% | Added+199.0% | 2026-03-31 |
| Wellington | fundamental | 290.1K | $1.20M | 0.00% | Added+7.0% | 2026-03-31 |
| Citadel | multi-strat | 283.7K | $1.18M | 0.00% | New | 2026-03-31 |
| DEShaw | quant | 18.1K | $75.32K | 0.00% | Trimmed-98.1% | 2026-03-31 |
| FidelityFMR | fundamental | 5.5K | $22.81K | 0.00% | Trimmed-63.1% | 2026-03-31 |
| TRowePrice | fundamental | 72.5K | $301 | 0.00% | Added+29.6% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-11upcoming | -0.12 | — | — |
| 2026-05-13 | -0.13 | -0.05 | +64.69% |
| 2026-03-04 | -0.12 | -0.14 | -18.08% |
| 2025-11-05 | -0.11 | -0.11 | -4.18% |
| 2025-08-11 | -0.17 | -0.12 | +32.27% |
| 2025-05-12 | -0.16 | -0.22 | -39.69% |
| 2025-03-05 | -0.13 | -0.16 | -21.28% |
| 2024-11-04 | -0.12 | -0.11 | +7.23% |
| 2024-08-06 | -0.11 | -0.01 | +88.33% |
| 2024-05-07 | -0.10 | -0.15 | -50.00% |
| 2024-03-05 | -0.07 | -0.09 | -31.00% |
| 2023-11-06 | -0.11 | -0.03 | +72.73% |
| 2023-08-07 | -0.12 | -0.10 | +16.67% |
| 2023-05-02 | -0.06 | 0.11 | +275.54% |
| 2023-03-07 | -0.23 | -0.23 | — |
| 2022-11-01 | -0.24 | -0.23 | +5.48% |